To see the other types of publications on this topic, follow the link: Plaque-type psoriasis, Psoriasis Area and Severity Index, Dermatology Life Quality Index.
Journal articles on the topic 'Plaque-type psoriasis, Psoriasis Area and Severity Index, Dermatology Life Quality Index'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Plaque-type psoriasis, Psoriasis Area and Severity Index, Dermatology Life Quality Index.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Roongpisuthipong, Wanjarus, Marinya Pongpudpunth, Chulaporn Roongpisuthipong, and Natta Rajatanavin. "The Effect of Weight Loss in Obese Patients with Chronic Stable Plaque-Type Psoriasis." Dermatology Research and Practice 2013 (2013): 1–5. http://dx.doi.org/10.1155/2013/795932.
Full textAbstract:
Background. Chronic plaque psoriasis is frequently associated with obesity. The effect of a low-calorie diet on psoriasis has not been investigated.Objective. The objective was to investigate whether moderate weight loss increases the therapeutic response to topical treatment in obese patients with chronic stable plaque-type psoriasis.Material and Method. A 24-week clinical trial was conducted in 10 patients. The efficacy of a low-calorie diet with topical treatment was compared with baseline in obese patients with chronic stable plaque-type psoriasis. The primary measure of clinical response was the Psoriasis Area and Severity Index at weeks 12 and 24.Results. At week 12, the mean reduction in body weight was 9.6 percent. There was an improvement from baseline of 50 percent or more in the Psoriasis Area and Severity Index in 50 percent of the patients. The responses as measured by improvements in the Psoriasis Area and Severity Index were paralleled by improvements in global assessments by the physician and the patients and in the Dermatology Life Quality Index.Conclusion. Obese patients with chronic stable plaque-type psoriasis increase their response to a low-calorie diet. Lifestyle modifications, including a low-calorie diet, may supplement the pharmacologic treatment of obese psoriasis patients.
2
Michalak-Stoma, Anna, Joanna Bartosińska, Małgorzata Kowal, Dorota Raczkiewicz, Dorota Krasowska, and Grażyna Chodorowska. "IL-17A in the Psoriatic Patients’ Serum and Plaque Scales as Potential Marker of the Diseases Severity and Obesity." Mediators of Inflammation 2020 (June 5, 2020): 1–9. http://dx.doi.org/10.1155/2020/7420823.
Full textAbstract:
The aim of the study was to evaluate concentrations of IL-17 in the serum and plaque scales of psoriatic patients. We analyzed their association with the clinical activity of the disease and with body mass index (BMI). Demographic data, medical history, serum, and scale from psoriatic plaques for assessment of IL-17 were collected from all the participants. The disease severity was assessed with PASI (Psoriasis Area and Severity Index), BSA (Body Surface Area), PGA (Physician Global Assessment), NAPSI (Nail Psoriasis Severity Index), and DLQI (Dermatology Quality of Life Index) scores. Obesity was diagnosed by calculating body mass index. Serum and scale concentration of IL-17 was determined with Human IL-17A High Sensitivity ELISA kit and Human IL-17 ELISA kit. In the psoriatic patients, BMI was statistically significantly higher than in the control group. Most of the patients presented BMI higher than normal. Our study confirms that overweight is a problem among psoriatic patients. A significant positive correlation between the IL-17 serum and scale concentrations and psoriasis severity indicates that IL-17 can be used as the marker of disease severity. More data from human studies can be crucial for understanding that relationship between IL-17, psoriasis, and obesity.
3
Poulin, Yves, Aditya K. Gupta, and John D. Amiss. "Efficacy of Etanercept in the Management of Plaque Psoriasis and Psoriatic Arthritis." Journal of Cutaneous Medicine and Surgery 11, no. 2_suppl (March 2007): S14—S22. http://dx.doi.org/10.2310/7750.2006.00070.
Full textAbstract:
Etanercept is a fully human dimeric fusion protein that reversibly binds tumor necrosis factor α. The first approved indication for etanercept was for the treatment of rheumatoid arthritis. It has also been shown to be highly efficacious in numerous large-scale trials for the treatment of plaque psoriasis; this indication was approved in Canada, the United States, and Europe. The recommended dosing of etanercept for plaque psoriasis is 50 mg twice weekly for 12 weeks, followed by a maintenance dose of 50 mg per week. Etanercept given at 50 mg twice weekly for 12 weeks significantly improved plaque psoriasis, as assessed by the Psoriasis Area and Severity Index (PASI), in which 75% reduction in PASI scores (PASI 75) has been the gold standard for judging effective therapy. Dosing given for 12 weeks produced PASI 75 rates of 47 to 49% in the phase 3 clinical trials. Longer treatment periods at this dosage have been investigated, from 24 to 48 weeks, with PASI 75 increasing to 63%. The importance of quality of life for psoriasis patients has been the focus of recent trials, and etanercept has been shown significant improvement in quality of life measures. Interim results from a phase 3b study suggest that etanercept may help reduce the burden of health care resources use by psoriatics. Etanercept has also shown efficacy in nail psoriasis. Case reports indicate that etanercept may be useful in psoriatic erythroderma, pustular psoriasis, guttate psoriasis, and palmopustular psoriasis. Etanercept is an effective biologic agent currently approved for the management of plaque psoriasis and psoriatic arthritis.
4
Sekar, Suganya, and Samuel J. Daniel. "A clinico-epidemiological study of psoriasis patients with moderate to severe plaque type in tertiary care centre in South India." International Journal of Research in Dermatology 7, no. 1 (December 24, 2020): 1. http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20204934.
Full textAbstract:
<p class="abstract"><strong>Background:</strong> Psoriasis is a chronic disorder with the most common manifestation being the plaque-type. Nearly 20% of the plaque type suffer from a disease of moderate to severe intensity with immense effect on the quality of life. Aim was to study the clinical, socio-economic and demographic characteristics of patients with moderate to severe plaque type of psoriasis.</p><p class="abstract"><strong>Methods:</strong> This was an observational study conducted in about fourty patients diagnosed with moderate to severe plaque type of psoriasis based upon the clinical history, morphology of the lesions and assessed using psoriasis area and severity index (PASI), dermatology life quality index (DLQI) scoring and for comorbidities. Data was compiled and analyzed with statistical package for social science (SPSS) Version 20.0.</p><p class="abstract"><strong>Results:</strong> Mean age was 37.43±10.1 years. 22 were males (55%) and 18 were females (45%). The mean duration was 8.93 years and 15% had family history. The mean age of onset was earlier in the females (20.23 years) with a positive family history, as compared to males (25.36 years). About 62.5% had moderate psoriasis and 37.5% had severe psoriasis. At the baseline the PASI score was 31.98±6.08 and DLQI score was 36. About 67.5% had nail changes and 10% had psoriatic arthritis. Almost in half (47.5%) the duration of the disease was 1 to 5 years and scalp (32.5%) the most common initial site of involvement. Various comorbidities were documented, 72% in moderate psoriasis and 73.33% in severe psoriasis with dyslipidemia (67.5%) being commonest.</p><p class="abstract"><strong>Conclusions:</strong> Patients with moderate to severe psoriasis mostly have a low quality of life with multiple significant co-morbidities that increases the risk for morbidity and mortality. </p>
5
Park, So Young, and Kon Hee Kim. "What Factors Influence on Dermatology-Related Life Quality of Psoriasis Patients in South Korea?" International Journal of Environmental Research and Public Health 18, no. 7 (March 31, 2021): 3624. http://dx.doi.org/10.3390/ijerph18073624.
Full textAbstract:
This descriptive study aimed to identify factors that can influence the quality of life of psoriasis patients. A total of 118 psoriasis outpatients completed a questionnaire consisting of the Dermatology Life Quality Index (DLQI), Psoriasis Life Stress Inventory (PLSI), Mishel Uncertainty in Illness Scale-Community form (MUIS-C), Center for Epidemiologic Studies-Depression scale (CES-D), and Self-Reported Severity Score (SRSS). The Psoriasis Area Severity Index (PASI) was calculated. The collected data were analyzed by descriptive statistics, t-test, one-way ANOVA, Scheffé test, Pearson’s correlation analysis, and stepwise multiple regression using SPSS/WIN 26.0. The average score of the DLQI was 14.19 ± 6.83 (range 0–30); the DLQI showed statistically significant differences according to age (F = 4.02, p = 0.021) and smoking type (F = 7.49, p = 0.001). The dermatology-related quality of life was significantly affected by psoriasis-related stress (β = 0.37, p < 0.001), depression (β = 0.35, p < 0.001), and subjective severity (β = 0.19, p = 0.005); these variables explained 60.7% of the variance in the dermatology-related quality of life (F = 61.34, p < 0.001). The results demonstrated that psoriasis-related stress, depression, and perceived severity of psoriasis should be considered when developing nursing interventions to improve patients’ quality of life.
6
Amy de la Breteque, M., A. Beauchet, N. Quiles-Tsimaratos, E. Estève, T. Le Guyadec, M. Ruer-Mulard, F. Maccari, et al. "Characteristics of patients with plaque psoriasis who have discordance between Psoriasis Area Severity Index and dermatology life quality index scores." Journal of the European Academy of Dermatology and Venereology 31, no. 5 (November 14, 2016): e269-e272. http://dx.doi.org/10.1111/jdv.14021.
Full text
7
Cassano, N., F. Loconsole, A. Galluccio, A. Miracapillo, M. Pezza, and G. A. Vena. "Once-Weekly Administration of High-Dosage Etanercept in Patients with Plaque Psoriasis: Results of a Pilot Experience (Power Study)." International Journal of Immunopathology and Pharmacology 19, no. 1 (January 2006): 205873920601900. http://dx.doi.org/10.1177/205873920601900123.
Full textAbstract:
Etanercept is a soluble tumour necrosis factor receptor fusion protein which is approved for the treatment of plaque psoriasis at the dose of either 25mg twice weekly (BIW) or, for the initial 12 weeks, 50mg BIW. Alternative dosing regimens have not been evaluated in psoriasis. In this study, we compare the efficacy and tolerability of two etanercept dosing regimens - 50mg BIW and 100mg once weekly (OW) - for 12 weeks in 108 patients with moderate-to-severe recalcitrant psoriasis. Efficacy measures included Psoriasis Area and Severity Index (PASI), severity of pruritus recorded on a visual analogue scale (VAS) and the influence on quality of life assessed by means of Dermatology Life Quality Index (DLQI). Both etanercept regimens caused a significant change in all the efficacy parameters after 4 weeks and 12 weeks, at a comparable rate. At week 12, a PASI improvement of at least 50% from baseline (PASI 50) was achieved by 74% of patients treated with 50mg BIW and 78% of patients treated with 100mg OW. A PASI 75 response was obtained in 54% and 50% of patients treated with 50mg BIW and 100mg OW, respectively. Treatment was well tolerated with similar type and frequency of adverse events between the two groups.
8
Stojkovic, Tatjana, Marina Hadzi-Pesic, Natasa Savic, and Ivan Stojkovic. "Evaluation of life quality in patients with psoriasis." Psihologija 48, no. 3 (2015): 267–77. http://dx.doi.org/10.2298/psi1503267s.
Full textAbstract:
Psoriasis is a disease that has a profound impact on all aspects of life quality because over years patients are faced not only with poor health, but also with a number of restrictions imposed by the disease in their professional, social and emotional life. The aim of the study was to assess the level of impairment to the life quality in patients with chronic plaque psoriasis in relation to the clinical status of the disease, disease duration, and age and gender of the examinees. The cross-sectional study was conducted at the Clinic for Skin and Venereal Diseases of the Clinical Center of Nis. The total sample consisted of 142 examinees, 82 in the primary group (patients with psoriasis), and 60 in the control group (healthy volunteers). In order to assess the impact of psoriasis on life quality and compare it to the life quality of healthy population, the DLQI questionnaire (Dermatology Life Quality Index)was used and the disease severity was estimated based on the value of the PASI score (Psoriasis Area and Severity Index). The results showed that the groups of examinees differ appreciably in self-assessment in all five dimensions of life quality. In patients with psoriasis, there was statistically significantly lower life quality as a reflection of the disease severity and subjective perceptions of the disease impact and treatment impact, but also as a result of a number of restrictions in daily functioning caused by the disease. Patients with a severer clinical status gave low ratings to their ability to function in all areas covered by the DLQI questionnaire, especially in the symptoms and feelings subscale. The results of our study indicate the importance of a multidisciplinary approach in the treatment of patients with psoriasis and the possibility of introducing a supportive therapy, which would, along with a regular dermatological therapy, notably improve the life quality of these patients.
9
G. V., Amruthavalli, Aruna V., and Gayathri R. "Clinical trial of combination therapy for the efficacy, safety, tolerability and improvements in quality of life in patients with moderate to severe plaque psoriasis." International Journal of Clinical Trials 5, no. 3 (July 24, 2018): 121. http://dx.doi.org/10.18203/2349-3259.ijct20183180.
Full textAbstract:
<p class="abstract"><strong>Background:</strong> Psoriasis is an autoimmune disorder with clinical manifestations scales, inflammation and dryness. The psoriatic skin behaves differently in concurrence with circadian rhythm. Cell division increases in late night and early morning hours. Enzymatic activity will be more during day time. To balance these variations a 24×7 protection is required. The objective of the present study is to find the improvement in Psoriasis condition with the Combination therapy compared to single drug usage.</p><p class="abstract"><strong>Methods:</strong> A clinical trial for 4 weeks was conducted among psoriasis patients with psorolin oil vs. combination therapy (Dr. JRK’s 777 oil, psorolin ointment, psorolin oil and psorolin medicated bathing bar) and the clinical relief was measured among both groups by following parameters like psoriasis area and severity index (PASI), Physician’s global assessment (PGA), dermatology life quality index (DLQI), subjective self-assessment questionnaire (SSAQ) and subject investigational product feedback questionnaire (SIPFBQ).</p><p class="abstract"><strong>Results:</strong> Combination therapy (1-3-2 topical therapy) of Dr. JRK’s 777 oil, psorolin ointment, psorolin oil and psorolin medicated bathing bar as a treatment regimen was found to be more effective in the treatment of psoriasis.</p><p class="abstract"><strong>Conclusions: </strong>1-3-2 topical therapy is useful in severe psoriasis conditions and recommended for long term effective treatment of psoriasis.</p><p class="abstract"> </p>
10
AlMutairi, Nawaf, and Tarek Nour. "Tofacitinib in Pediatric Psoriasis: An Open-Label Trial to Study Its Safety and Efficacy in Children." Dermatology 236, no. 3 (October 30, 2019): 191–98. http://dx.doi.org/10.1159/000503062.
Full textAbstract:
Introduction: Psoriasis is a chronic, multifactorial, inflammatory disorder, with an estimated prevalence of 0.71% in children. The commonly used therapeutic agents target the underlying inflammation. Tofacitinib has demonstrated efficacy in adult psoriasis. Aim: To study the efficacy, safety, and tolerability of tofacitinib in pediatric patients with moderate to severe chronic plaque psoriasis. Methods: The study included children aged between 8 and 17 years, with moderate to severe psoriasis, given tofacitinib 5 mg orally twice daily for at least 36 weeks. The clinical response was estimated using the Psoriasis Area and Severity Index (PASI) score, Physician’s Global Assessment (PGA), and the Children’s Dermatology Life Quality Index (CDLQI). The incidence and severity of adverse events (AEs) were meticulously recorded in each case. Results: A total of 47 patients, with a median age of 12.3 years, completed the study. At week 12, 55.32% achieved PASI 75, and 70.21% at week 36. PGA of clear or almost clear responses at week 12 were 59.57 and 65.96%, respectfully, at week 36. Relatively few and mostly minor adverse effects were noted. No severe AEs were reported. Conclusion: The treatment with tofacitinib was safe and well tolerated, and led to significant improvement of their disease and quality of life as reflected in CDLQI scores. However, the results need to be validated in larger multicenter trials.
11
Philipp, Sandra. "Psoriasis: Wechsel der Medikamentenklasse bei Nichtansprechen?" Kompass Dermatologie 8, no. 1 (2020): 16–18. http://dx.doi.org/10.1159/000505056.
Full textAbstract:
Background: Switching between biologics is commonly performed for the management of plaque psoriasis. However, no evidence about switching from secukinumab to ustekinumab has been reported. Methods: This retrospective observational multicenter study aimed to describe efficacy and safety of ustekinumab in secukinumab nonresponder patients. Results: A total of 21 patients unresponsive to secukinumab were treated with ustekinumab for a mean period of 53.3 weeks. Ustekinumab was effective in reducing disease severity, with significant improvements of both psoriasis area severity index (PASI) and dermatology quality of life index (DLQI) scores. PASI score improvements of 31.8, 44, 77.8, 80.3, 80.5, and 89.6%, at week 4, 12, 24, 36, 48, and above 60 weeks, respectively, were detected (p<0.05), achieving PASI 50, 75, and >90 responses in 93.8, 87.5, and 50% of patients at week 48. Four patients withdrew from ustekinumab treatment because of inefficacy, and failure of multiple biologic agents (>2) seemed to affect ustekinumab drug survival. No serious adverse events (AEs) were reported while 38.1% of patients experienced mild AEs. Conclusion: Ustekinumab was safe and effective in treating patients unresponsive to secukinumab.
12
Rojano Rada, Jairo, Paulette Terán Pereira, and Liliana López Grassa. "Clinical and epidemiological characterization of patients with psoriasis and the prescription of biological therapy in Venezuela: a cross-sectional study." Medwave 20, no. 10 (November 30, 2020): e8064-e8064. http://dx.doi.org/10.5867/medwave.2020.10.8064.
Full textAbstract:
Introduction Psoriasis is a chronic disease that affects the skin. One hundred twenty-five million people around the world suffer from this condition. In specific groups of patients, the joints may also be involved. To control and follow-up patients with psoriasis, psoriasis area severity and dermatological quality of life measurements were established. Both parameters are necessary for the initiation of biological therapy, as specified in the psoriasis management guide (2015) of the national committee of rheumatological, immunological, and bone metabolism diseases of the Venezuelan Institute of Social Security. Objective To characterize the clinical and epidemiological variables and the prescription of biological therapy in patients with psoriasis who access the high-cost dispensing program of the Venezuelan Institute Social Security (IVSS) pharmacy. Methods This is a descriptive, cross-sectional study. Results A total of 374 patient records were assessed. The male gender was more frequent, with 56.1% (p <0.001), mostly from Caracas city. In comparing age groups with sex, a difference among these was observed (p <0.05). 57.5% previously used methotrexate, 6.68% biological, 3.2% topical steroids, and 31% did not report which type of previous therapy they had received. Amongst the clinical presentations, 70% corresponded to plaque psoriasis. 79% of the patients presented moderate activity according to the Psoriasis Area and Severity Index (PASI): Eleven percent were assessed with the Dermatology Life Quality Index (DLQI); 39% of them reported an extremely important effect. The anergic range of the Mantoux test represented 70.9% of the cases, and 0.3% took the booster evaluation. Chest X-ray was reported normal in 95% of the cases. The most demanded biological medicine was etanercept, in 52% of the cases. Conclusions Male gender and its association with psoriasis was an important finding. The need to improve the administrative components in completing the medication request formats and strengthen clinical measurements and good medical practice was also found.
13
Chiricozzi, Andrea, Andrea Conti, Martina Burlando, Giulia Odorici, Francesca Gaiani, Salvatore Panduri, and Piergiorgio Malagoli. "Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience." Dermatology 235, no. 3 (2019): 213–18. http://dx.doi.org/10.1159/000497274.
Full textAbstract:
Background: Switching between biologics is commonly performed for the management of plaque psoriasis. However, no evidence about switching from secukinumab to ustekinumab has been reported. Methods: This retrospective observational multicenter study aimed to describe efficacy and safety of ustekinumab in secukinumab nonresponder patients. Results: A total of 21 patients unresponsive to secukinumab were treated with ustekinumab for a mean period of 53.3 weeks. Ustekinumab was effective in reducing disease severity, with significant improvements of both psoriasis area severity index (PASI) and dermatology quality of life index (DLQI) scores. PASI score improvements of 31.8, 44, 77.8, 80.3, 80.5, and 89.6%, at week 4, 12, 24, 36, 48, and above 60 weeks, respectively, were detected (p < 0.05), achieving PASI 50, 75, and > 90 responses in 93.8, 87.5, and 50% of patients at week 48. Four patients withdrew from ustekinumab treatment because of inefficacy, and failure of multiple biologic agents (> 2) seemed to affect ustekinumab drug survival. No serious adverse events (AEs) were reported while 38.1% of patients experienced mild AEs. Conclusion: Ustekinumab was safe and effective in treating patients unresponsive to secukinumab.
14
Bedwal, Ankita, Kavitha Rajarathna, and Revathi T.N. "A Randomized, Prospective Study to Compare the Efficacy and Safety of Omega-3 Fatty Acids as Additional Therapy to Methotrexate versus Methotrexate Monotherapy in the Management of Moderate to Severe Plaque Psoriasis." Pharmacology and Clinical Pharmacy Research 6, no. 1 (March 27, 2021): 1. http://dx.doi.org/10.15416/pcpr.v6i1.30836.
Full textAbstract:
Psoriasis is a chronic, inflammatory, hyperproliferative, immune-mediated skin disorder, having a prevalence of 0.44-2.8% in India. Methotrexate is a widely used systemic regimen for moderate to severe psoriasis. Supplementation of omega-3 fatty acids has decreased the severity of the disease in some studies. This study aimed to assess the efficacy and safety of omega-3 fatty acids as an add-on to methotrexate versus methotrexate monotherapy in patients with moderate to severe plaque psoriasis. A total of 40 patients with moderate to severe plaque psoriasis were recruited in the study and randomized into two groups of 20 patients each. Group O received omega-3 fatty acids as add-on to methotrexate and Group M received methotrexate monotherapy. Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), Physician’s Global Assessment (PGA) were assessed at baseline, 4 weeks, 8 weeks and 12 weeks of treatment. The adverse events were assessed throughout the study period. There was a significant decrease in PASI and DLQI scores from baseline to end of 12 weeks in both groups (p<0.001) but the difference between the two groups was not significant (p>0.05). A higher number of patients had a PGA score of 0 or 1 at the end of 12 weeks in Group O (60%) as compared to Group M (40%) but the difference between the groups was not significant (p=0.34). The treatment was well tolerated in both the groups, with most common adverse events being nausea, diarrhea and epigastric pain. This study showed that the treatment in both the groups was equally effective in decreasing the severity of psoriasis and was well tolerated.
15
Tao, Xing-Bao, Yin-Qiu Huang, Yi-Hong Zhou, Lv-Lang Zhang, and Yao-Kai Chen. "Efficacy and safety of guselkumab for the treatment of patients with moderate-to-severe plaque psoriasis: A metaanalysis of randomized clinical trials." Tropical Journal of Pharmaceutical Research 19, no. 2 (April 9, 2020): 433–40. http://dx.doi.org/10.4314/tjpr.v19i2.28.
Full textAbstract:
Purpose: To conduct a systematic analysis on data from randomized controlled trials (RCTs) on different doses of guselkumab, and provide high-quality evidence for its use in the treatment of patients with moderate-to-severe plaque psoriasis (PsO).
Methods: Related studies were searched using online search engines including MEDLINE, PubMed, and central registry of Cochrane controlled trials from January 2001 to October 2017. Only randomized, placebo-controlled, double-blind clinical trials involving guselkumab- and placebo-treated PsO subjects were included.
Results: Five eligible double-blind, randomized, and placebo-controlled trials involving patients with moderate-to-severe PsO subjects treated with guselkumab were included. Compared with the placebo groups, the proportion of patients with improvements in Psoriasis Area and Severity Index (PASI) 75 (RR= 12.14; 95% CI= 9.11-16.16; p < 0.001); PASI 90 (RR= 23.26; 95% CI =14.57-37.13; p < 0.001), and PASI 100 (RR = 37.66; 95% CI = 15.81-89.69; p < 0.001) were significantly higher than those in guselkumab-treated groups. Furthermore, the guselkumab-treated groups showed significant decreases in Physician’s Global Assessment (PGA) score (RR = 10.46; 95% CI = 7.96-13.83; p < 0.001) and the Dermatology Life Quality Index (DLQI) score (SMD = -1.3; 95% CL = -1.4 to -1.19; p < 0.001), when compared with the placebo groups. However, there were no significant differences in adverse events (AEs) (RR = 1.01; 95% CL = 0.93-1.11; p > 0.05); severe adverse events (SAEs) (RR = 1.32; 95% CI =0.69-2.54; p > 0.05) and study discontinuations (RR = 0.79; 95% CI = 0.42-1.48; p > 0.05) between the two groups.
Conclusion: This meta-analysis summarizes available evidence for the use of guselkumab in psoriasis. The results suggest that guselkumab is superior to placebo in moderate-to-severe psoriasis, and is welltolerated, effective, and safe in improving the severity of disease and quality of life.
Keywords: Guselkumab, Effectiveness, Safety, Plaque psoriasis, Meta-analysis, Quality of life
16
Kutlu, Ömer, and Hatice M. Eksioglu. "Evaluation of ustekinumab treatment in psoriasis and the potential effect of metabolic syndrome on treatment response: a single center retrospective study." International Journal of Research in Dermatology 6, no. 4 (June 23, 2020): 505. http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20202656.
Full textAbstract:
<p class="abstract"><strong>Background:</strong> Ustekinumab is a biological agent used in the treatment of psoriasis. This study evaluated the treatment response of psoriasis patients who received ustekinumab.</p><p class="abstract"><strong>Methods:</strong> The study included nine patients with plaque-type psoriasis who received ustekinumab treatment. Clinical response of all patients was evaluated with psoriasis area and severity index (PASI), dermatology life quality index (DLQI), and psoriasis disability index (PDI) at 0, 4, 16 and 28 weeks. The patients were also evaluated for metabolic syndrome and its effect on treatment response.<strong></strong></p><p class="abstract"><strong>Results:</strong> A total of five male and four female patients with psoriasis vulgaris were included in the study. At the end of 28th weeks, 55% of the patients reached PASI 75 score. The mean PASI scores of the patients at weeks 0, 4, 16, 26 and 28 were 36.98±12.28, 8.86±9.06, 9.52±11.55, 3.55±3.61 and 6.98±6.40, respectively. Although not statistically significant, at the 28th weeks, the mean PASI, DLQI and PDI values of the patients with metabolic syndrome were higher than those without metabolic syndrome (p=0.505, p=0.314, p=0.786, respectively).</p><p class="abstract"><strong>Conclusions:</strong> Ustekinumab is an effective treatment option for patients with psoriasis who resistant to conventional and biological treatments. In resistant cases to the ustekinumab, the routine treatment interval should be reduced. Psoriasis patients with accompanying metabolic syndrome may have a lower response rate than those without metabolic syndrome to biological agents.</p>
17
Scanlon, James V., Benjamin P. Exter, Michael Steinberg, and Courtney I. Jarvis. "Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis." Annals of Pharmacotherapy 43, no. 9 (August 11, 2009): 1456–65. http://dx.doi.org/10.1345/aph.1m151.
Full textAbstract:
Objective: To systematically review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of ustekinumab to inform pharmacists and other healthcare professionals of this new biologic therapy for psoriasis. Data Sources: A search of PubMed/MEDLINE, EMBASE, and International Pharmaceutical Abstracts was performed through July 2009, limited to publications in English, using the search terms CNTO-1275, ustekinumab, interleukin-12, interleukin-23, and/or psoriasis to identify literature sources. References from the retrieved articles were also evaluated to identify relevant literature. An abstract from a Congress of the European Academy of Dermatology and Venereology and unpublished Phase 3 clinical trials in progress (using www.clinicaltrials.gov ) were also reviewed. The Food and Drug Administration, European Medicines Agency, and Health Canada Web sites were used to retrieve product monographs, regulatory guidances, and advisory committee briefing packets. Study Selection and Data Extraction: All available studies relevant to the pharmacology, pharmacokinetics, and clinical safety/efficacy of ustekinumab for the treatment of psoriasis were included, with preference for human data. Data Synthesis: Ustekinumab, an anti-interleukin-12/23 monoclonal antibody, achieved the primary endpoint of 75% reduction in the Psoriasis Area and Severity Index score in a large proportion of patients in the Phase 3 PHOENIX trials. Commensurate improvements were also seen in the Physician's Global Assessment and Dermatology Life Quality Index scores. These efficacy results were reproduced in the ACCEPT trial, demonstrating superiority of ustekinumab to etanercept. The frequency of adverse events was similar between ustekinumab and placebo; common adverse events reported included nasopharyngitis, upper respiratory tract infection, headache, arthralgia, cough, and injection site reactions. Phase 3 studies indicate that the optimal dosing appears to be 45 mg for patients weighing less than 100 kg or 90 mg for patients weighing more than 100 kg, with both doses administered subcutaneously. In these studies, the second dose was given 4 weeks after the first and then every 8–12 weeks thereafter, based upon response. Conclusions: Ustekinumab, a promising new therapy, reduces the extent and severity of psoriasis and was well tolerated in clinical trials. Ongoing clinical trials will allow clinicians to further assess the efficacy/safety profile of this novel biologic.
18
Loveman, E., D. Turner, D. Hartwell, K. Cooper, and A. Clegg. "Infliximab for the treatment of adults with psoriasis." Health Technology Assessment 13, Suppl 1 (June 2009): 55–60. http://dx.doi.org/10.3310/hta13suppl1-09.
Full textAbstract:
This paper presents a summary of the evidence review group (ERG) report into the clinical and cost-effectiveness of infliximab for the treatment of moderate to severe plaque psoriasis, in accordance with the licensed indication, based on the evidence submission from Schering-Plough to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The outcomes stated in the manufacturer’s definition of the decision problem were severity [Psoriasis Area and Severity Index (PASI) score], remission rates, relapse rates and health-related quality of life. The main evidence in the submission comes from four randomised controlled trials (RCT) comparing infliximab with placebo and eight RCTs comparing either etanercept or efalizumab with placebo. At week 10, patients on infliximab had a significantly higher likelihood of attaining a reduction in PASI score than placebo patients. There were also statistically significant differences between infliximab and placebo in the secondary outcomes. In the comparator trials both the efalizumab and etanercept arms included a significantly higher proportion of patients who achieved a reduction in PASI score at week 12 than the placebo arms. No head-to-head studies were identified directly comparing infliximab with etanercept or efalizumab. The manufacturer carried out an indirect comparison, but the ERG had reservations about the comparison because of the lack of information presented and areas of uncertainty in relation to the included data. The economic model presented by the manufacturer was appropriate for the disease area and given the available data. The cost-effectiveness analysis estimates the mean length of time that an individual would respond to infliximab compared with continuous etanercept and the utility gains associated with this response. The base-case incremental cost-effectiveness ratio (ICER) for infliximab compared with continuous etanercept for patients with severe psoriasis was £26,095 per quality-adjusted life-year. A one-way sensitivity analysis, a scenario analysis and a probabilistic sensitivity analysis were undertaken by the ERG. The ICER is highly sensitive to assumptions about the costs and frequency of inpatient stays for non-responders of infliximab. The guidance issued by NICE in August 2007 as a result of the STA states that infliximab within its licensed indication is recommended for the treatment of adults with very severe plaque psoriasis, or with psoriasis that has failed to respond to standard systematic therapies. Infliximab treatment should be continued beyond 10 weeks in people whose psoriasis has shown an adequate response to treatment within 10 weeks. In addition, when using the Dermatology Life Quality Index (DLQI), care should be taken to take into account the patient’s disabilities, to ensure DLQI continues to be an accurate measure.
19
Tolkacheva, Daria Georgievna, Valeria Dmitrievna Sokolova, and Vladimir Valentinovich Mladov. "Effectiveness and Safety of Targeted Drugs for the Treatment of Adults with Moderate-to-severe Plaque Psoriasis in the Russian Federation." Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор), no. 4 (38) (December 1, 2019): 76–86. http://dx.doi.org/10.31556/2219-0678.2019.38.4.076-086.
Full textAbstract:
Multiple randomised controlled trials (RCTs) have compared the efficacy of targeted therapies for the treatment of moderate-to-severe plaque psoriasis with placebo. However, the relative effectiveness of these treatments is not studied sufficiently. The aim of this study was to compare the effectiveness and safety of targeted drugs (netakimab, ixekizumab, guselkumab, secukinumab, ustekinumab, certolizumab, infliximab, adalimumab, etanercept, tofacitinib and apremilast) in adult patients with moderate-to-severe plaque psoriasis using such outcomes as PASI 75/90/100, PGA/IGA, DLQI, AEs, SAEs and withdrawals due to AEs. Material and methods. We performed a systematic literature review in PubMed database and in the CENTRAL section of Cochrane library (Embase filter) to identify relevant RCTs. The primary outcome was Psoriasis Area and Severity Index (PASI) 75 response at week 12 of treatment. Other analyzed outcomes: PASI 90/100, Physician’s Global Assessment (PGA) /IGA, Dermatology Life Quality Index (DLQI), number of patients suffering from at least one adverse event (AE) / severe AE and number of patient withdrawals from the study due to AE during initial 12 weeks of treatment. For each outcome we conducted network meta-analyses (NMAs) and univariate meta-regression analyses to adjust for baseline risk differences and cross-trial differences. Results. We selected 35 RCTs. We conducted several types of NMAs for each outcome to avoid bias in research. In most cases random effects NMAs adjusted to differences in placebo response rate provided the best model fit statistics and were selected for interpretation. Pairwise indirect comparisons from most NMAs suggested IL-17 inhibitors (netakimab and ixekizumab) along with IL-23 inhibitor guselkumab have superior effectiveness and favorable safety profile compared to other targeted therapies used to treat adults with moderate-to-severe plaque psoriasis during initial 12 weeks of therapy based on PASI 75/90/100, PGA/IGA, and DLQI.
20
Yang, Jing, Zongming Wang, and Xilin Zhang. "Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials." Journal of Immunology Research 2020 (July 17, 2020): 1–8. http://dx.doi.org/10.1155/2020/4975628.
Full textAbstract:
Background. To investigate the efficacy and safety of guselkumab in the treatment of moderate-to-severe plaque psoriasis. Methods. A systematic review was undertaken to identify double-blind randomized controlled trials (RCTs). PubMed, Web of Science, Cochrane Library, EMBASE, and Google Scholar databases were searched before 1 March 2020. The odds ratios (ORs) with 95% confidence interval (CI) were calculated. All analyses were conducted with intention-to-treat basis. A range of sensitivity analyses was undertaken. Results. A total of 7 articles contained 1206 plaque psoriasis patients with guselkumab, 585 patients with placebo, and 1250 patients with adalimumab were included. The results indicated that guselkumab had better efficacy than placebo or adalimumab for Psoriasis Area and Severity Index score reductions from baseline of 75% (PASI 75) (OR=61.37, 95% CI=31.15 to 120.91; OR=3.08, 95% CI=2.35 to 4.06), Investigator’s Global Assessment scores of 0 or 1 (IGA 0/1) (OR=65.75, 95% CI=45.54 to 94.95; OR=2.79, 95% CI=2.17 to 3.59), and Dermatology Life Quality Index scores of 0 or 1 (DLQI 0/1) (OR=29.64, 95% CI=18.80 to 46.73; OR=1.86, 95% CI=1.50 to 2.31). The guselkumab had similar safety with placebo or adalimumab about the incidence of adverse events (AEs) (OR=1.05, 95% CI=0.86 to 1.29; OR=0.97, 95% CI=0.79 to 1.19) and serious adverse events (SAEs) (OR=1.03, 95% CI=0.47 to 2.27; OR=0.91, 95% CI=0.44 to 1.87). Meanwhile, there was no statistically significant association of infections and serious infections compared with the placebo or adalimumab group. The guselkumab was more effective and had the similar tolerance. Conclusion. The guselkumab had excellent efficacy and great safety in moderate-to-severe plaque psoriasis, but long-term safety remained to be determined.
21
Cameron, C., C. Druchok, B. Hutton, S. McElligott, S. Nair, A. Schubert, A. Situ, A. Varu, and R. Villacorta. "Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis." Journal of Psoriasis and Psoriatic Arthritis 4, no. 2 (December 27, 2018): 81–92. http://dx.doi.org/10.1177/2475530318818816.
Full textAbstract:
Background: Guselkumab is an interleukin-23 inhibitor indicated for treatment of moderate-to-severe plaque psoriasis. Objective: The objective was to determine the relative efficacy and safety of guselkumab compared to other biologics. Methods: A systematic review was performed to identify randomized controlled trials (RCTs). Bayesian network meta-analyses (NMAs) were conducted using meta-regression analyses that adjusted for cross-trial differences and risk differences. The primary outcome was Psoriasis Area and Severity Index (PASI) 90 response. Other efficacy and safety outcomes were considered. Several meta-regressions were performed to account for variations in patient and study characteristics: baseline risk adjustment (ie, control group response), prior biologic use, duration of psoriasis, weight, age, race, and baseline PASI/dermatology life quality index scores. The best-fitting model using predefined criteria was selected. Results: Forty-five RCTs were identified. Patient and study characteristics differed between RCTs as reflected in variations in control group response. Both the baseline risk-adjusted NMA and the risk-difference NMA fit the data best and suggested guselkumab has one of the highest PASI 90 responses. Pairwise comparisons from the baseline risk-adjusted PASI 90 NMA suggested guselkumab has comparable efficacy with ixekizumab (relative risk [RR]: 0.999, 95% credible intervals [CrIs]: 0.89-1.13) and brodalumab (RR: 1.04, 95% CrIs: 0.91-1.17) and superior efficacy versus all other treatments in the network (RR range, 1.20 to 43.22). Guselkumab was superior or comparable to other therapies for other efficacy outcomes and had a more favorable safety profile than most. Conclusions: Guselkumab has one of the highest PASI 90 responses among psoriasis treatments; similar findings were observed for other efficacy outcomes. Guselkumab has a favorable benefit–risk balance compared to moderate-to-severe psoriasis therapies.
22
Khadka, D. K., S. Agrawal, and T. K. Dhali. "Methotrexate Versus Methotrexate Plus Folic Acid in the Treatment of Moderate to Severe Plaque Psoriasis: A Randomized Clinical-Trial." Nepal Journal of Dermatology, Venereology & Leprology 14, no. 1 (September 28, 2016): 29–36. http://dx.doi.org/10.3126/njdvl.v14i1.15835.
Full textAbstract:
Background: Psoriasis is a chronic, recurring inflammatory disease affecting the skin, joints and nails that has a significant negative impact on the quality of life. Efficacy of methotrexate versus combination of methotrexate plus folic acid in the treatment of psoriasis has been rarely assessed.Objectives: To compare the efficacy of methotrexate versus methotrexate plus folic acid in the treatment of moderate to severe chronic plaque psoriasisMaterial and Methods: Eighty patients with moderate to severe chronic plaque psoriasis were randomized to receive either methotrexate (group A) or methotrexate plus folic acid (group B). End point of treatment was 75% reduction in Psoriasis Area and Severity Index (PASI 75) score or upto 3 months, whichever was earlier. Patients were then followed up for a period of 12 weeks for assessment of relapse, DLQI and adverse effects.Results: Of 80 patients, 71 completed the treatment and follow up period (33 in group A, and 38 in group B). PASI 75 was achieved in 34/40(85%) patients in group A and 32/40(80%) patients in group B (P < 0.142). There was statistically significant number of patients who had greater adverse effect in methotrexate than in methotrexate plus folic acid (p=0.020). There was significant difference in the number of patients who relapsed during the follow-up period (P = 0.013) with more relapse in group B.Conclusion: Combination of methotrexate and folic acid developed lesser adverse effect and greater relapse in comparison to methotrexate alone.Nepal Journal of Dermatology, Venereology & Leprology, Vol.14(1) 2016, pp.29-36
23
Sondermann, Wiebke. "Pustulosis palmoplantaris: Langfriste Kontrolle im Blick." Kompass Dermatologie 9, no. 2 (2021): 82–84. http://dx.doi.org/10.1159/000515961.
Full textAbstract:
Im Rahmen der sog. 2PRECISE-Studie, einer multizentrischen, randomisierten, doppelblinden Phase 3b Parallel-Studie, wurden Patienten mit mittelschwerer bis schwerer PPP (palmoplantarer Psoriasis Area and Severity Index (PPPASI) ≥12 und Dermatology Life Quality Index (DLQI) ≥10) über 52 Wochen mit Secukinumab bzw. Placebo behandelt. Der primäre Endpunkt der Studie war die Bestimmung der Rate der Patienten mit einem ppPASI75 unter Therapie mit Secukinumab in Woche 16 gegenüber Placebo. Es wurde ein Signifikanzlevel von 2,5% zugrunde gelegt. 79 Patienten erhielten Secukinumab in einer Dosierung von 300mg und 80 Patienten wurden mittels Secukinumab 150mg behandelt. 78 Patienten wurden der Placebo-Gruppe zugeordnet. Ab Woche 16 erhielten 27 Patienten aus der Placebo-Gruppe 150mg Secukinumab und 28 Patienten 300mg Secukinumab. 10 Patienten hatten auf Placebo angesprochen. In Woche 16 erreichten 26,6% der mit 300mg Secukinumab behandelten Patienten und 17,5% der Patienten unter 150mg Secukinumab einen ppPASI75 im Vergleich zu 14,1% der mit Placebo behandelten Patienten (P = 0,0411). Der primäre Endpunkt wurde nicht erreicht, jedoch ergab sich eine Odds Ratio (OR) von 2,62 (95% Konfidenzintervall, 1,04–6,60) zugunsten von 300mg Secukinumab gegenüber Placebo. In Woche 52 wiesen 41,8% der mit 300mg Secukinumab behandelten Patienten und 35,0% der Patienten unter Secukinumab 150mg einen ppPASI75 auf. Das klinische Ansprechen der Patienten, die auch unter einer Plaque Psoriasis litten, war besser als das der Patienten mit einer reinen PPP. Die Lebensqualitätsverbesserung gemessen mit dem DLQI war unter 300mg Secukinumab deutlich besser als unter Placebo. In Woche 16 erreichten 13% der Patienten unter Secukinumab 300mg einen DLQI von 0 oder 1, während es unter Placebo nur 4,3% der Patienten waren. Es wurden in der Studie keine unerwarteten unerwünschten Ereignisse beobachtet.
24
Schmitt, Jochen, and Gottfried Wozel. "The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis." Dermatology 210, no. 3 (2005): 194–99. http://dx.doi.org/10.1159/000083509.
Full text
25
Gupta, Aditya K., and Elizabeth A. Cooper. "Psoriatic Nail Disease: Quality of Life and Treatment." Journal of Cutaneous Medicine and Surgery 13, no. 5_suppl (September 2009): S102—S106. http://dx.doi.org/10.2310/7750.2009.00027.
Full textAbstract:
Nail psoriasis is common among patients with plaque psoriasis or psoriatic arthritis and has a detrimental effect on quality of life. However, there are currently no standardized therapeutic regimens for nail psoriasis. Traditional treatments for nail psoriasis, which include topical, intralesional, and oral therapies, may be time-consuming, painful, or unsafe when administered long term. Biologic therapies have demonstrated efficacy for plaque psoriasis and psoriatic arthritis; these therapies may be particularly promising for the treatment of nail psoriasis as both groups of patients have an elevated incidence of nail dystrophy. The biologic therapies adalimumab, alefacept, efalizumab, etanercept, and infliximab have demonstrated clinically important nail psoriasis improvements using the Nail Psoriasis Severity Index, a helpful tool that, upon validation, will allow comparison across treatments and trials. Large-scale, long-term trials using standardized outcome measures are needed to further evaluate biologic therapies for the treatment of nail psoriasis.
26
Basnet, Binamra, Annu Ranjit, Anil Subedi, Shristi Shrestha, and Saraswoti Neupane. "Effect of Psoriasis on Quality of life." Nepal Journal of Dermatology, Venereology & Leprology 16, no. 1 (March 29, 2018): 49–52. http://dx.doi.org/10.3126/njdvl.v16i1.19407.
Full textAbstract:
Introduction: Psoriasis is one of the common skin disorders which has a significant distressing effects on patients due to its chronicity, joint involvement, therapy related side effects and its impact on physical appearance.Objective: To find out impairment in quality of life among patients with psoriasis.Materials and Methods: Patients attending the Dermatology outpatient department of Gandaki Medical College were recruited for the study from December 2016 to July 2017. Dermatology Life Quality Index (DLQI) was used to assess the psychosocial involvement.Results: Significant increase in DLQI scores depicting graver psychosocial involvement in females compared to males was observed (p=0.038). Comparison between severity of disease and DLQI scores showed a positive correlation but was not statistically significant (r=0.22 & p=0.187). When we compared the type of psoriasis with severity of disease, chronic plaque psoriasis showed significant statistical correlation (p=0.003).Conclusion: Females tend to experience significant impairment in quality of life compared to males. Further studies with more sample size are needed to consolidate or rectify our findings.
27
Leon, Argentina, Kourosh Beroukhim, Melissa Danesh, Catherine Nguyen, Kristina Lee, Benjamin Farahnik, Tian Hao Zhu, et al. "The Correlation between the Dermatology Life Quality Index and the Psoriasis Area Severity Index." Journal of Psoriasis and Psoriatic Arthritis 1, no. 1 (December 2015): 26–30. http://dx.doi.org/10.1177/247553031500100104.
Full text
28
Hesselvig, J., A. Egeberg, N. Loft, C. Zachariae, K. Kofoed, and L. Skov. "Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab." Acta Dermato Venereologica 98, no. 3 (2018): 335–39. http://dx.doi.org/10.2340/00015555-2833.
Full text
29
Silva, Maria Flavia Pereira da, Maria Rita Parise Fortes, Luciane Donida Bartoli Miot, and Silvio Alencar Marques. "Psoriasis: correlation between severity index (PASI) and systemic treatment." Anais Brasileiros de Dermatologia 88, no. 5 (October 2013): 760–63. http://dx.doi.org/10.1590/abd1806-4841.20132052.
Full textAbstract:
BACKGROUND: Psoriasis is a chronic inflammatory disease of the skin that affects patients of all ages andboth genders. The impact of the disease on quality of life is greater among patients with moderate to severe psoriasis. OBJECTIVE: to establish a correlation between the psoriasis area and severity index (PASI) and theDermatology Life Quality Index (DLQI) based on a quality of life questionnaire adapted to the Brazilian contextfor patients with plaque psoriasis before and after systemic treatment. METHODS: This was a cross-sectional, descriptive study of psoriasis patients who did not undergo treatment or who manifested clinical activity of the disease. Patients were evaluated according to the PASI and the quality of life questionnaire adapted to theBrazilian context before and 60 days after systemic treatment. RESULTS: Thirty-five patients participated in thestudy. Twenty-six were men, with a mean age of 46 years. There was no correlation between the PASI and thequality of life questionnaire adapted to the Brazilian context, but there was a correlation between the PASI andsome items of the quality of life questionnaire adapted to the Brazilian context, such as jobs involving public contact. CONCLUSION: The non-correlation between the PASI and the quality of life questionnaire adapted to the Brazilian context in this work may be associated with a history of chronic disease, which implies greater acceptance of the illness, or may be related to the low income and social status of the patients studied. The correlationobserved among patients with careers involving public contact suggests that some professions are more impacted by the disease. It may be necessary to adapt the quality of life questionnaire to patients with a low income andcultural and social limitations. The small sample size (n=35 patients) and the short follow-up period of 60 dayswere some of the limitations of this work.
30
Patel, Mital, Stephanie W. Liu, Abrar Qureshi, and Joseph F. Merola. "The Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B-SNIPI): A Novel Index to Measure All Non-plaque Psoriasis Subsets." Journal of Rheumatology 41, no. 6 (June 2014): 1230–32. http://dx.doi.org/10.3899/jrheum.140177.
Full textAbstract:
Psoriasis is a chronic inflammatory disease that encompasses a large spectrum of clinically distinct subtypes. Although chronic plaque psoriasis is reported as the most common form of psoriatic skin disease, there is growing evidence that other variants including scalp, nail, inverse, and palmoplantar psoriasis are prevalent, undertreated, and associated with significant impairment in quality of life. Currently, the Psoriasis Area and Severity Index (PASI) is the standard to assess psoriasis severity as well as response to treatment; however, the PASI has several limitations. In response to this need and as a complementary objective measure to the PASI, we created the Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B-SNIPI), based on patient-surveyed, patient-reported outcomes equally weighted with physician assessment of disease activity. Herein we summarize the B-SNIPI as presented at the 2013 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
31
Khare, Shikha, and Sudha Agrawal. "Clinico-Epidemiological Characteristics and Impact on Quality of Life in Psoriatic Patients with and without Nail Changes - A Nepalese Experience." Journal of Evidence Based Medicine and Healthcare 8, no. 06 (February 8, 2021): 306–12. http://dx.doi.org/10.18410/jebmh/2021/60.
Full textAbstract:
BACKGROUND Nail involvement in psoriasis is likely to influence the quality of life (QOL) because of its highly visible site; however, the impact of this disease on QOL is an underexplored area. Similarly, the relationship between severity of skin involvement and nail involvement has been overlooked. The study was conducted to evaluate the clinico-epidemiological characteristics of psoriasis patients with and without nail changes and assess the health-related quality of life (HRQOL). Furthermore, the correlation of severity of nail involvement with the severity of skin involvement and its impact on quality of life was assessed. METHODS A total of 370 adult psoriasis patients with or without nail changes was studied. Skin severity was assessed by body surface area (BSA) and Psoriasis Area and Severity Index (PASI) while nail severity was assessed using Nail Psoriasis Severity Index (NAPSI). Patients’ quality of life was measured using the Nepali Version of Dermatology Life Quality Index (DLQI). RESULTS Nail psoriasis was more prevalent in males in both the groups; females were having more nail involvement (0.041). There were no significant diff erences in other clinico-epidemiologic characteristics between these two groups except the late onset of psoriasis in the age group > 30 years, scalp involvement and absence of family history of psoriasis (P ≤ 0.05). There was a strong positive correlation between the age of onset of skin changes with age of onset of nail involvement (r = 0.799) and the joint involvement (r = 0.742) as well as the age of onset of joint involvement with nail changes (r = 0.838). The mean PASI was 7.265 ± 7.153 vs. 6.189 ± 7.153 in patients with > 10 vs. ≤ 10 total NAPSI score and it was statistically significant (P = 0.011), however, there was a moderate positive correlation between PASI and NAPSI (r = 0.32). Almost half of psoriasis patients had very large to extremely large effects on quality of life but leisure and treatment domain were affected more amongst patients with nail changes. Early onset of joint involvement, body surface area of > 3 % involvement and PASI score > 5 had significant effect on quality of life. CONCLUSIONS The nail involvement is an important finding in determining the severity of skin involvement and had very large to extremely large effect on quality of life particular on leisure and treatment domain. Therefore, nail examination must be done in all psoriatic patients. KEYWORDS Nail Psoriasis, Quality of Life, Dermatology Life Quality Index, Psoriasis Area and Severity Index, Nail Psoriasis Severity Index
32
Gupta, Aditya K., Richard G. Langley, Charles Lynde, Kirk Barber, Wayne Gulliver, Gilles Lauzon, Launa J. Aspeslet, Robert T. Foster, Robert B. Huizinga, and Randall W. Yatscoff. "ISA247: Quality of Life Results from a Phase II, Randomized, Placebo-Controlled Study." Journal of Cutaneous Medicine and Surgery 12, no. 6 (November 2008): 268–75. http://dx.doi.org/10.2310/7750.2008.07060.
Full textAbstract:
Background: Psoriasis is a chronic skin condition that can negatively affect a patient's quality of life (QoL), often hindering social functioning. ISA247, a novel psoriatic agent, has shown clinical efficacy in moderate to severe psoriasis sufferers, but its effect on QoL is currently not reported. Objective: The objective of this study was to assess the effect of ISA247 on the QoL in patients with stable, plaque-type psoriasis. Methods: A phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter study assessed the effects of ISA247 doses of 0.5 mg/kg/d ( n = 77) or 1.5 mg/kg/d ( n = 83) compared with placebo ( n = 41) for 12 weeks. QoL was assessed using the Dermatology Life Quality Index (DLQI) and Psoriasis Disability Index (PDI) scales. Results: ISA247 treatment (pooled groups) significantly improved QoL scores as assessed by both the DLQI and the PDI compared with those receiving placebo ( p < .05). Treatment with the higher dose of 1.5 mg/kg/d demonstrated a significantly greater response to many of the QoL scales compared with the 0.5 mg/kg/d group ( p < .05). Conclusions: ISA247 appears to improve the QoL while also providing effective treatment for chronic, moderate to severe, plaque-type psoriasis.
33
Menter, Alan. "The Effect of Psoriasis on Patients' Quality of Life and Improvements Associated with Alefacept Therapy." Journal of Cutaneous Medicine and Surgery 8, no. 2_suppl (December 2004): 20–25. http://dx.doi.org/10.1177/12034754040080s205.
Full textAbstract:
Patients with psoriasis may experience impaired psychosocial mental status regardless of their objectively defined disease severity. The objective clinical measures of disease that are commonly used to evaluate a patient's psoriasis fail to take into account the effect of psoriasis on patients' quality of life (QOL). As a result, a significant number of patients are dissatisfied with conventional treatments and are searching for new options. A high unmet need for effective and safe long-term therapies that can also improve patients' QOL exists in psoriasis. Alefacept, a selective biologic agent specifically designed for the treatment of psoriasis, provides improvement in both the physical (as measured by the Psoriasis Area and Severity Index) and mental (as measured by the Dermatology Life Quality Index) aspects of the disease. Additionally, alefacept is extremely well tolerated, with no negative effect on QOL, and the improvement in QOL is maintained off-treatment, which is consistent with its remittive effects on the disease. Alefacept helps fulfill the needs of psoriasis patients by providing efficacy, safety, off-treatment remissions, and improvement in QOL.
34
Prevezas, Christos, Alexander C. Katoulis, Evangelia Papadavid, Pantelis Panagakis, and Dimitrios Rigopoulos. "Short-Term Correlation of the Psoriasis Area Severity Index, the Nail Psoriasis Area Severity Index, and the Dermatology Life Quality Index , before and after Treatment, in Patients with Skin and Nail Psoriasis." Skin Appendage Disorders 5, no. 6 (2019): 344–49. http://dx.doi.org/10.1159/000499348.
Full text
35
Mikhael, Dalia, Kelly Babcock, and Jean-Pierre DesGroseilliers. "Cost Comparison of Psoriasis Treatments." Journal of Cutaneous Medicine and Surgery 13, no. 6 (November 2009): 303–7. http://dx.doi.org/10.2310/7750.2009.08088.
Full textAbstract:
Background: Knowledge of the cost of various psoriasis therapeutic options is essential to the prescribing clinician. Objective: To compare the cost of various psoriasis treatments over a 10-year period in the province of Ontario, Canada. Methods: We used a hypothetical patient with plaque-type psoriasis of moderate severity with a Psoriasis Area and Severity Index of 10, body surface area of 20%, and no joint involvement. The costs to treat this hypothetical patient with different therapeutic regimens were compared in this study. Results: In a 60 kg patient, alefacept was the most costly form of therapy, based on two 12-week treatments per year, followed by infliximab 5 mg/kg. In a 90 kg patient, infliximab 5 mg/kg was the most costly, followed by alefacept. The least costly treatment was ultraviolet B phototherapy. Conclusion: With the knowledge of these data, informed prescribing by the dermatologist may reduce the financial burden to the patient, the provincial health care system, and insurance companies.
36
Mittal, Ankit, Sunil Dogra, Tarun Narang, and Aman Sharma. "Pilot Study to Evaluate the Efficacy and Safety of Oral Tacrolimus in Adult Patients With Refractory Severe Plaque Psoriasis." Journal of Cutaneous Medicine and Surgery 20, no. 3 (November 9, 2015): 228–32. http://dx.doi.org/10.1177/1203475415616964.
Full textAbstract:
Background: Tacrolimus, a congener of cyclosporine, has replaced cyclosporine as a first-line treatment for most transplant patients due to its superior efficacy and safety. Tacrolimus has not been extensively studied for the treatment of psoriasis. Objectives: To study the efficacy and safety of oral tacrolimus in adult patients with severe refractory plaque psoriasis. Methods: This was an open-label pilot study. Patients with severe plaque type psoriasis who were unresponsive to at least 1 systemic treatment were treated with oral tacrolimus. Results: Thirty patients were treated. After 12 weeks, improvement in mean Psoriasis Area Severity Index (PASI) score was 80.37% ( P < .001), PASI 75 was observed in 19 of 26 (73.1%) patients, and PASI 90 was observed in 11 of 26 (42.3%) patients. No severe side effects were noted. Conclusion: Oral tacrolimus is an effective and safe option for the short-term treatment of severe plaque psoriasis.
37
Gulliver, Wayne, Charles Lynde, Jan P. Dutz, Ronald B. Vender, Jensen Yeung, Marc Bourcier, Pierre-Luc Dion, Chi-Ho Hong, Gordon Searles, and Yves Poulin. "Think beyond the Skin." Journal of Cutaneous Medicine and Surgery 19, no. 1 (January 2015): 22–27. http://dx.doi.org/10.2310/7750.2014.13151.
Full textAbstract:
Objective: Explore the feasibility of Treat to Target in the area of psoriasis as seen in other therapeutic areas such as hypertension, hyperlipidemia, diabetes and rheumatoid arthritis. Methods: Review validated, measurable targets for psoriasis, including physician global assessment (PGA), psoriasis area and severity index (PASI) and dermatology life quality index (DLQI). Examine principles brought forth in the published European consensus on psoriasis and develop a Canadian consensus on Treat to Target in psoriasis. Results: As PASI and DLQI are not routinely used in the community setting, we are recommending target at a PGA of zero (clear). Conclusion: Recommend that the target is a PGA of zero (clear) as it provides a simple and measurable result that the patient and physician can clearly understand.
38
Sendrasoa, Fandresena Arilala, Naina Harinjara Razanakoto, Volatantely Ratovonjanahary, Onivola Raharolahy, Irina Mamisoa Ranaivo, Malalaniaina Andrianarison, Mendrika Fifaliana Rakotoarisaona, et al. "Quality of Life in Patients with Psoriasis Seen in the Department of Dermatology, Antananarivo, Madagascar." BioMed Research International 2020 (September 15, 2020): 1–5. http://dx.doi.org/10.1155/2020/9292163.
Full textAbstract:
Background. Psoriasis is a chronic, inflammatory, and multifactorial dermatosis that impairs quality of life (QoL). Health-related QoL has become an important element in medical decision-making along with the effectiveness and the harmlessness of the treatments. Objective. To assess the impact of psoriasis in the QoL of patients with psoriasis by using the DLQI scales. Methods. A cross-sectional study from January to June 2018 was conducted in the Department of Dermatology of the University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar, including patients more than 18 years old with mild to severe psoriasis. The severity of psoriasis was assessed using the “Psoriasis Area and Severity Index (PASI)”. QoL of patients with psoriasis was evaluated by using the DLQI scales. Results. 80 patients were included, their mean age was 36.5 years, and the male to female was 1.5 : 1. The mean DLQI score was 13.8. Symptoms, feelings, and psychic were the most altered dimensions. QoL was impaired in young patients, single, having medium level education. Even though patients with disease duration more than 5 years had higher DLQI score than other patients, the difference was not statistically significant (p=0.36). Furthermore, the clinical presentation of psoriasis did not influence the patient’s QoL (p=0.73). Patients with nail involvement had QoL impaired but the difference with another localization was not statistically significant (p=0.2). The quality of life was influenced by body area involved. The higher the body surface area involved, the more QoL is impaired (p=0.002). Furthermore, the higher the PASI, the more QoL is altered (p=0.002). Conclusion. Psoriasis has a negative impact in the quality of life in Malagasy patients with psoriasis, especially in younger and single patients. Worse quality of life is correlated to severity of psoriasis.
39
Wasel, Norman, Yves Poulin, Robin Andrew, Daphne Chan, Elisa Fraquelli, and Kim Papp. "A Canadian Self-Administered Online Survey to Evaluate the Impact of Moderate-to-Severe Psoriasis among Patients." Journal of Cutaneous Medicine and Surgery 13, no. 6 (November 2009): 294–302. http://dx.doi.org/10.2310/7750.2009.08066.
Full textAbstract:
Background: Few population studies of individuals living with psoriasis have been performed in Canada. Objective: The objective of this survey was to understand the severity and impact of psoriasis on the lives of Canadian patients. Methods: An online survey was conducted using a consumer panel. Eligible subjects reported a diagnosis of psoriasis and provided a self-reported level of severity. In addition, subjects had to either (a) have psoriasis covering at least 3% of their body surface area; (b) have psoriasis on a sensitive area of the body; or (c) be currently undergoing treatment for their psoriasis with systemic medication and/or phototherapy. Results: A total of 514 panelists met the inclusion criteria and completed the survey. Current moderate, severe, or very severe psoriasis was reported by 65% of respondents. Nearly all subjects (96%) had psoriasis affecting a sensitive area of the body. At the time of the survey, 18% were taking systemic medication and/or phototherapy. Comorbidities, such as obesity and high blood pressure, were highly prevalent, with 75% of respondents reporting at least one other diagnosis. Data from the SF-8 and Dermatology Life Quality Index instruments indicated that psoriasis negatively impacted quality of life. Conclusion: Moderate-to-severe psoriasis places a burden on Canadian patients, some of whom may be receiving suboptimal treatment or treatment not appropriate for the severity of their condition.
40
Mohammad Samiul Huq, Abu Hena Chowdhury, Towhida Noor, and Saleheen Huq. "Psycho-social determinants and magnitude of public health problems of psoriasis in Bangladesh." World Journal of Advanced Research and Reviews 10, no. 2 (May 30, 2021): 108–18. http://dx.doi.org/10.30574/wjarr.2021.10.2.0207.
Full textAbstract:
Background: Numerous studies have analyzed the influence of psoriasis on the quality of life and psychological health of patients. 0nly few studies have addressed the effect of the disease on individuals and cohabitants of psoriatic patients in developing countries, none in Bangladesh. Objective: To assess the clinical severity, the physical and psychosocial disability and to analyze their interrelationship in psoriasis patients and cohabitants. Methods: Hospital based cross-sectional study was conducted. The study included patients and cohabitants. The questionnaire was administered to the patient. Their quality of life was measured with the Psoriasis Disability index (PDI) and Family Dermatology Life Quality index (FDLQI), and their psychological state with Psoriasis life stress inventory (PLSI). The clinical severity by psoriasis area severity index (PASI) score. Appropriate test conducted using SPSS software. Result: 225 patients (138 males, 87 female) were included in the study. The clinical PASI scores correlated significantly with the over all physical disability PDI (<0.0001), stress incurred PLSI (<0.0001), FDLQI (<0.0001) and individual aspects of the PDI. The higher the PASI index, the higher the PDI, PLSI and FDLQI scores, which indicated greater impact on QOL. Among the physical and psychological factors analyzed, daily activity, employment, leisure and treatment were reported to be affected the most. Relative of female patients worries most. Conclusion: Psoriasis markedly worsens the global well-being of patients and their cohabitants, who experienced an impairment of their quality of life and higher levels of anxiety and depression.
41
Sultana, Abida, Md Saiful Islam Bhuiyan, Md Nur Hossain Bhuiyan, ASM Zakaria, Md Mustafizur Rahman, and Md Nizamuddin. "Efficacy of Mycophenolate Mofetil (Mmf) in the Treatment of Chronic Plaque Type Psoriasis." Journal of Chittagong Medical College Teachers' Association 23, no. 1 (September 22, 2012): 46–48. http://dx.doi.org/10.3329/jcmcta.v23i1.51895.
Full textAbstract:
One to two percent of world population is suffering from psoriasis and treating moderate and severe psoriasis is a huge challenge as most of the systemic anti-psoriatics cause long term toxicities. The aim of the study was to see the efficacy and of Mycophenolate mofetil (MMF) in the treatment of moderate to severe plaque type psoriasis. It was an open prospective study conducted in the department of Dermatology and Venereology, Dhaka Medical College, Dhaka and Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka. Seven patients with moderate to severe plaque type psoriasis were treated with MMF 1gm twice daily for twelve weeks. Outcome was measured with Psoriasis Area and Severity Index (PASI) and adverse effects were recorded. Baseline PASI was 10.8 to 30 and PASI reduction after 4, 8 and 12 weeks treatment was 23.70% to 43.75%, 49.5% to 70.37% and 75.0% to 88.89% respectively. PASI-75 (PASI reduction >75.0% was achieved in all seven cases. No adverse effect was found. Mycophenolate Mofetil (MMF) is a effective treatment option for moderate to severe plaque type psoriasis.
JCMCTA 2012; 23(1): 46-48
42
Ohata, Chika, Bungo Ohyama, Fumi Kuwahara, Eri Katayama, and Takekuni Nakama. "Fingernail Involvement is a Bigger Burden Than Face and Scalp Involvement in Patients With Psoriasis." Journal of Psoriasis and Psoriatic Arthritis 4, no. 1 (October 16, 2018): 28–30. http://dx.doi.org/10.1177/2475530318806256.
Full textAbstract:
Background: Psoriasis can cause considerable emotional distress. There are a small amount of data regarding this subject. Objective: To evaluate distress in patients with psoriasis. Methods: We studied the impact of scalp, face, and fingernail involvement in 118 patients with psoriasis between October 2017 and March 2018 in Kurume University Hospital using Dermatology Life Quality Index (DLQI). Results: Dermatology Life Quality Index was significantly higher in patients with scalp, face, and fingernail involvement. Psoriasis area and severity index (PASI) was significantly higher in those with scalp and face involvement; however, no significant difference was found in the PASI of the patients with and without fingernail involvement. In the subcohorts with low PASI, there was no significant difference of DLQI between patients with and without scalp and face involvement; however, DLQI in patients with fingernail involvement was significantly higher than that in those without nail involvement. Conclusion: Fingernail involvement is a big burden even in patients with mild psoriasis.
43
Parimalam, K., and S. Sanjeetha Fathima. "Dermatological life quality index in psoriasis out patients: the changing trend." International Journal of Research in Dermatology 5, no. 1 (January 25, 2019): 170. http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20190239.
Full textAbstract:
<p class="abstract"><strong>Background:</strong> Psoriasis is a chronic inflammatory disease characterized by remissions and exacerbations, having great impact on social and psychological aspects. From mild plaque psoriasis to more severe pustular and erythrodermic forms with or without joint involvement, is known to have a negative impact on QOL (Quality of Life). Appropriate treatment will improve both disease outcome and QOL in patients. The objective of the study was to assess QOL in psoriasis patient of different age group, type, duration and severity of disease, and their response to this assessment.</p><p class="abstract"><strong>Methods:</strong> A cross sectional study was done with pretested DLQI questionnaire on 101 psoriasis patients, in a government hospital. Interpretation of score and impact on QOL was done and graded as mild, moderate, considerable, severe and very severe.<strong></strong></p><p class="abstract"><strong>Results:</strong> In our study, females outnumbered males with male female ratio of 1:1.5. The mean age 39.56±16.029 years. No significant association was noted between grade of affection and demographic variants. Most of them had moderate impact on QOL. QOL was worst affected in patients <5 years of disease duration. 85% of the patients felt happy & 15% felt neutral on being evaluated by this questionnaire.</p><p class="abstract"><strong>Conclusions:</strong> It is suggested that DLQI is assessed in all new/patients with less than 5 years of disease. Appropriate systemic/photo therapy to be initiated even in mild disease if there is negative impact on the QOL. Assessment of QOL strengthens the doctor-patient rapport and improves better patient adherence to therapy and achieves faster and better control of the disease.</p>
44
Philipp, Sandra. "Nagelpsoriasis: Anti-IL17-Therapie ist erfolgversprechend." Kompass Dermatologie 8, no. 3 (2020): 111–13. http://dx.doi.org/10.1159/000509299.
Full textAbstract:
Background: Nail psoriasis is associated with functional impairment, pain and reduced quality of life. Objectives: To demonstrate the superiority of secukinumab over placebo in clearing nail psoriasis as assessed by the Nail Psoriasis Severity Index (NAPSI) at week 16 and over time up to week 132. Presented here is the week 32 interim analysis. Impact on quality of life was assessed by Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) patient questionnaires. Methods: TRANSFIGURE is a double-blind, randomized, placebo-controlled study in patients with moderate-to-severe plaque and nail psoriasis. Results: The primary objective of this study was met: both doses of secukinumab were superior to placebo at week 16 (NAPSI improvements of -45,3%, -37,9% and -10,8% for secukinumab 300 mg and 150 mg and placebo, respectively, P<0,001). Significant improvements were seen in patients’ quality of life: the NAPPA-Quality of Life total score median decreases at week 16 were 60,9%, 49,9% and 15,8% for secukinumab 300 mg and 150 mg and placebo, respectively (P < 0_001). Improvement in nail psoriasis continued to week 32: NAPSI percentage change reached -63,2% and -52,6% for secukinumab 300 mg and 150 mg, respectively. Skin clearance measured by ≥90% improvement in Psoriasis. Area and Severity Index was significant (rates of 72,5%, 54,0% and 1,7% for secukinumab 300mg and 150mg and placebo at week 16, respectively, P<0,001) and was sustained to week 32. The most common adverse events were nasopharyngitis, headache and upper respiratory tract infections. Conclusion: Secukinumab demonstrated significant and clinically meaningful efficacy and quality-of-life improvements for patients with nail psoriasis up to week 32.
45
Gottlieb, Alice B., Bruce Strober, Mark Lebwohl, Roland Kaufmann, David Pariser, Redzinaldas Narbutas, Judit Nyirady, et al. "Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data." Journal of Psoriasis and Psoriatic Arthritis 2, no. 2 (March 2017): 73–80. http://dx.doi.org/10.1177/247553031700200206.
Full textAbstract:
Background Psoriasis negatively affects patients’ quality of life. Secukinumab is a human interleukin-17A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis. Objectives The current analysis evaluated the benefits of secukinumab by assessing relationships between disease severity and patient-reported symptoms. Methods Correlations between psoriasis-related itching, pain, and scaling and disease severity scores (Psoriasis Area and Severity Index [PASI] and Investigator's Global Assessment [IGA]) were evaluated at baseline, Week 12, and change from baseline to Week 12 using secukinumab clinical data from ERASURE and FIXTURE. Symptom responder status and PASI/IGA change were evaluated using logistic modeling. Results Correlation coefficients ranged 0.11-0.49 for PASI and 0.19-0.52 for IGA. Greater PASI response was related to greater symptom response/complete relief. Conclusions Results further demonstrate the relationship between traditional clinical measures of disease severity and patient-reported, psoriasis-related itching, pain, and scaling –- hence the need to consider both outcomes together to evaluate treatment effects in this disease fully.
46
Berg, Scott H., Esther A. Balogh, Rima I. Ghamrawi, and Steven R. Feldman. "A review of secukinumab in psoriasis treatment." Immunotherapy 13, no. 3 (February 2021): 201–16. http://dx.doi.org/10.2217/imt-2020-0195.
Full textAbstract:
Psoriasis is a systemic immunologic disorder associated with decreased quality of life and numerous co-morbidities, including psoriatic arthritis and cardiovascular disease. Secukinumab, a fully human IgG1 monoclonal antibody, selectively binds IL-17A and is approved by the US FDA and European Medicines Agency for moderate-to-severe plaque psoriasis and psoriatic arthritis. This review examines the efficacy and safety of secukinumab for the treatment of psoriasis using the literature retrieved from the PubMed database. In clinical trials, treatment with secukinumab led to rapid and sustained improvement in Psoriasis Area and Severity Index (PASI) scores, with PASI 90 response rates up to 68.5% at 5 years. Long-term clinical trial and real-world data have established secukinumab as a safe and effective treatment for psoriasis.
47
Houghton, Katherine, Dhaval Patil, Braulio Gomez, and Steven R. Feldman. "Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab." Dermatology and Therapy 11, no. 4 (June 10, 2021): 1373–84. http://dx.doi.org/10.1007/s13555-021-00564-2.
Full text
48
Gupta, Aditya K., and Andréa M. Cherman. "Efalizumab in the Treatment of Psoriasis." Journal of Cutaneous Medicine and Surgery 10, no. 2 (March 2006): 57–68. http://dx.doi.org/10.2310/7750.2006.00014.
Full textAbstract:
Background: Efalizumab (anti-CD11a), a targeted, reversible T-cell modulator, is a humanized monoclonal antibody that provides a rapid onset of action of clinical benefit and has been studied up to 36 months, showing continuous control of plaque-type psoriasis. Efalizumab has recently been approved in Canada for this indication. Objective: To examine the efficacy and safety of efalizumab by presenting the latest data in the treatment of psoriasis. Methods: We searched MEDLINE (1966–2005) for randomized, double-blind studies of efalizumab (1 mg/kg for 12 weeks) using the following key words: psoriasis, efalizumab, biologics, and treatment. Results: It was found that the proportion of patients who achieved Psoriasis Area and Severity Index (PASI) 75 and PASI 50 ranged from 22 to 39% and 52 to 61%, respectively. PASI 75 improvement was achieved in 44% of patients, who continued to receive efalizumab by week 24. Following 36 months of continuous treatment, a PASI 75 response was achieved by 45% (intent-to-treat [ITT] analysis), 59% (maintenance group analysis), and 73% (as-treated analysis). Its safety profile was similar during the 12-week and 36-month treatment periods. Conclusions: Currently, more than 3,500 patients have received efalizumab in clinical trials. Efalizumab may be an important treatment option for dermatologists seeking to provide a well-tolerated and effective treatment modality for patients with moderate to severe chronic plaque psoriasis.
49
Joseph Swithin Fernando and Sathya Narayanan Rajendran. "Evaluation of psoriasis area and severity index and its correlation with DLQI in evaluating various parameters in psoriasis – A hospital-based study." International Journal of Research in Pharmaceutical Sciences 11, SPL4 (December 21, 2020): 2149–53. http://dx.doi.org/10.26452/ijrps.v11ispl4.4435.
Full textAbstract:
Psoriasis is a common chronically relapsing autoinflammatory disease of the skin affecting patients of all ages and both genders. There is a more significant impact on the quality of life in patients with established disease. The study was conducted to correlate the relation between dermatology life quality index and psoriasis area and severity index and thereby deriving the impact of one on the other. This is a cross-sectional, descriptive study undertaken in psoriasis patients who had disease manifestations but did not undergo any treatment. Patient’s DLQI and PASI were calculated at a given point of time. Fifty patients participated in the study. Thirty-three patients were men, with a mean age of 37 years, and seventeen patients were women with a mean age of 34 years. PASI & DLQI were tabulated and compared with age, gender, disease duration, occupation etc. PASI is a reliable parameter to measure the severity of disease and DLQI for measuring the quality of life in psoriatic patients. PASI and DLQI are reliable parameters, and combining both and correlating them with various demographic and lifestyle parameters gives a clear indication of how these influence the disease impact in general.
50
Paek, So Yeon, Jordan M. Thompson, Abrar A. Qureshi, Joseph F. Merola, and M. Elaine Husni. "Comprehensive Assessment of the Psoriasis Patient (CAPP): A Report from the GRAPPA 2015 Annual Meeting." Journal of Rheumatology 43, no. 5 (May 2016): 961–64. http://dx.doi.org/10.3899/jrheum.160115.
Full textAbstract:
Outcome measures for psoriasis severity are complex because of the heterogeneous presentation of the disease. At the 2015 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members introduced the Comprehensive Assessment of the Psoriasis Patient (CAPP), a novel disease severity measure to more accurately assess the full burden of plaque psoriasis and subtypes, including inverse, scalp, nail, palmoplantar, and genital psoriasis. The CAPP is based on a 5-point physician’s global assessment for 7 psoriasis phenotypes and incorporates visual analog scale–based, patient-derived, patient-reported outcomes. By quantifying disease effects of plaque psoriasis, 6 other psoriasis subtypes, as well as quality of life and daily function, the CAPP survey identifies a subset of psoriasis patients with moderate to severe psoriasis that would not be considered moderate to severe when assessed by the Psoriasis Area and Severity Index. The current version of CAPP is focused entirely on psoriasis. Feedback from our industry colleagues and collaborators has suggested that a psoriatic arthritis (PsA) measure may be important to include in the CAPP. At the 2015 GRAPPA meeting, we administered a survey to 106 GRAPPA members to determine whether a PsA measure should be included. A majority (74%) of respondents across all professions agreed that the CAPP should include a measure of PsA. Although responses varied widely on how PsA should be measured, a majority of the respondents reported that presence of PsA in both peripheral and axial joint assessment was important.